Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Cash & Equivalents (2017 - 2022)

Historic Cash & Equivalents for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $20.5 million.

  • Iterum Therapeutics' Cash & Equivalents fell 4305.76% to $20.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $20.5 million, marking a year-over-year decrease of 4305.76%. This contributed to the annual value of $27.4 million for FY2021, which is 8917.84% up from last year.
  • As of Q3 2022, Iterum Therapeutics' Cash & Equivalents stood at $20.5 million, which was down 4305.76% from $9.2 million recorded in Q2 2022.
  • Over the past 5 years, Iterum Therapeutics' Cash & Equivalents peaked at $84.9 million during Q2 2018, and registered a low of $4.8 million during Q4 2019.
  • For the 5-year period, Iterum Therapeutics' Cash & Equivalents averaged around $33.6 million, with its median value being $30.1 million (2019).
  • As far as peak fluctuations go, Iterum Therapeutics' Cash & Equivalents surged by 42505.6% in 2018, and later plummeted by 8922.36% in 2019.
  • Iterum Therapeutics' Cash & Equivalents (Quarter) stood at $44.6 million in 2018, then tumbled by 89.22% to $4.8 million in 2019, then soared by 202.19% to $14.5 million in 2020, then surged by 89.18% to $27.4 million in 2021, then decreased by 25.35% to $20.5 million in 2022.
  • Its Cash & Equivalents was $20.5 million in Q3 2022, compared to $9.2 million in Q2 2022 and $31.4 million in Q1 2022.